Developing a new targeted therapy with minimal side effects and toxicity to improve the outcome of childhood AML
Dr Jenny Wang, Children’s Cancer Institute, Sydney.
Funding period: 2019-2022.
This research project is kindly supported through the Estate of Florence Brown.
Acute myeloid leukaemia (AML) is a fatal form of blood cancer in children. The survival of AML patients remains poor due to the return of disease after chemotherapy (relapse). Leukaemia stem cells (LSCs) are the major cause of relapse and Dr Wang and the team at the Children’s Cancer Institute are studying how to eradicate them without harming healthy cells.
This project will develop a novel LSC-targeted therapy with minimal side effects and toxicity that will improve the dismal outcome of childhood AML.
Last updated on July 30th, 2020
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.